A randomized, double-blind, placebo-controlled study of ibrutinib, a Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).
作者
Margaret A. Tempero,Lisa M. Coussens,Lawrence H. Fong,Robert Manges,Priyanka A. Singh,Yunfeng Li,George W. Cole,Danelle Frances James,Josep M. Tabernero
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins] 日期:2016-05-20卷期号:34 (15_suppl): TPS2601-TPS2601被引量:8
标识
DOI:10.1200/jco.2016.34.15_suppl.tps2601
摘要
TPS2601 Background: Advanced pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor prognosis and short survival. Nab-paclitaxel/gemcitabine (Nab-P/GCB) is a preferred front-line treatment regimen. The Bruton tyrosine kinase (BTK) inhibitor ibrutinib (ibr) demonstrates antitumor activity in preclinical PDAC models, due in part to modulation of the tumor microenvironment. Ibr treatment inhibits mast-cell degranulation and decreases tumor-associated inflammation and desmoplasia; simultaneously, ibrutinib enhances the presence and activity of cytotoxic T cells in tumors (Affara et al, Cancer Cell, 2014; Masso-Valles et al, Cancer Res, 2015; Gunderson et al, Cancer Discov, 2015). This study will evaluate the efficacy of ibr in combination with Nab-P/GCB. Methods: The randomized, multicenter, double-blind, phase 2/3 RESOLVE trial (NCT02436668; PCYC-1137-CA) compares ibr vs. placebo, in combination with Nab-P/GCB, in approximately 320 patients with previously untreated metastatic pancreatic carcinoma. Eligibility criteria include confirmed metastatic pancreas carcinoma within 6 weeks of randomization; adequate organ function; and Karnofsky performance score ≥ 70. Key exclusion criteria include previous treatment (chemotherapy for primary PDAC, BTK inhibitor), and history of stroke or intracranial hemorrhage within 6 months. Patients will be randomized to oral ibr (560 mg) or matched placebo given daily in combination with Nab-P (125 mg/m2) and GCB (1,000 mg/m2) on days 1, 8, and 15 of a 28-day cycle until disease progression or treatment is no longer tolerated. A safety run-in phase evaluates the ibr combination prior to the randomization phase of the study. The primary endpoint is progression-free survival; secondary endpoints include overall survival and safety. Enrollment in the trial is ongoing. Results: N/A Conclusions: N/A Clinical trial information: NCT02436668.